NEW YORK (GenomeWeb) – Belgian diagnostics company MDxHealth reported before the opening of the market on Thursday that its full-year 2016 revenues rose 70 percent, driven by strong growth in its ConfirmMDx prostate cancer test and the launch of its SelectMDx liquid biopsy test.

The company reported total revenues of $30.0 million, up from $17.6 million in 2015. Of the total, US revenues rose 60 percent to $24.4 million from $15.2 million in 2015, and non-US revenues rose 133 percent to $5.6 million from $2.4 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.